Stat3-mediated Atg7 expression enhances anti-tumor immunity in melanoma

Stat3-mediated Atg7 expression enhances anti-tumor immunity in melanoma | bioRxiv /* */ /* */ <!-- <!-- /*! * yepnope1.5.4 * (c) WTFPL, GPLv2 */ (function(a,b,c){function d(a){return"[object Function]"==o.call(a)}function e(a){return"string"==typeof a}function f(){}function g(a){return!a||"loaded"==a||"complete"==a||"uninitialized"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){("c"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&&g(l.readyState)&&(u.r=o=1,!q&&h(),l.onload=l.onreadystatechange=null,b)){"img"!=a&&m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&&y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&&(r=1,y[c]=[]),"object"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height="0",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),"img"!=a&&(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||"j",e(a)?i("c"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&&h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName("script")[0],o={}.toString,p=[],q=0,r="MozAppearance"in l.style,s=r&&!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&&"[object Opera]"==o.call(a.opera),l=!!b.attachEvent&&!l,u=r?"object":l?"script":"img",v=l?"script":u,w=Array.isArray||function(a){return"[object Array]"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&&(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split("!"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f<d;f++)g=a[f].split("="),(e=z[g.shift()])&&(c=e(c,g));for(f=0;f<b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(".").pop().split("?").shift(),i.bypass||(e&&(e=d(e)?e:e[a]||e[g]||e[a.split("/").pop().split("?")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&&"css"==i.url.split(".").pop().split("?").shift()?"c":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&&f.load(function(){k(),e&&e(i.origUrl,h,g),j&&j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&&b++;return b}(),a)a.hasOwnProperty(n)&&(!c&&!--m&&(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&&a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&&l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&&c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!='dataLayer'?'&l='+l:'';j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;j.type='text/javascript';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-M677548'); Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search New Results Stat3-mediated Atg7 expression enhances anti-tumor immunity in melanoma Sarah M. Zimmerman , Erin Suh , Sofia R. Smith , George P. Souroullas doi: https://doi.org/10.1101/2024.06.10.598284 Sarah M. Zimmerman 1 Department of Medicine, Washington University School of Medicine in St. Louis , St. Louis, Missouri 63110, USA 2 Division of Oncology, Molecular Oncology Section, Washington University School of Medicine in St. Louis , St. Louis, Missouri 63110, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Erin Suh 4 University of Georgia , Athens, GA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sofia R. Smith 1 Department of Medicine, Washington University School of Medicine in St. Louis , St. Louis, Missouri 63110, USA 2 Division of Oncology, Molecular Oncology Section, Washington University School of Medicine in St. Louis , St. Louis, Missouri 63110, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site George P. Souroullas 1 Department of Medicine, Washington University School of Medicine in St. Louis , St. Louis, Missouri 63110, USA 2 Division of Oncology, Molecular Oncology Section, Washington University School of Medicine in St. Louis , St. Louis, Missouri 63110, USA 3 Siteman Comprehensive Cancer Center, Washington University School of Medicine in St. Louis , St. Louis, Missouri 63110, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: george.souroullas{at}wustl.edu Abstract Full Text Info/History Metrics Preview PDF ABSTRACT Epigenetic modifications to DNA and chromatin control oncogenic and tumor suppressive mechanisms in melanoma. EZH2, the catalytic component of the Polycomb repressive complex 2 (PRC2), which mediates methylation of lysine 27 on histone 3 (H3K27me3), can regulate both melanoma initiation and progression. We previously found that mutant Ezh2 Y641F interacts with the immune regulator Stat3 and together they affect anti-tumor immunity. However, given the numerous downstream targets and pathways affected by EZH2, many mechanisms that determine its oncogenic activity remain largely unexplored. Using genetically engineered mouse models we further investigated the role of pathways downstream of EZH2 in melanoma carcinogenesis and identified significant enrichment in several autophagy signatures, along with increased expression of autophagy regulators, such as Atg7. In this study, we investigated the effect of Atg7 on melanoma growth and tumor immunity within the context of an Ezh2 Y641F epigenetic state. We found that expression of Atg7 is largely dependent on Stat3 expression and that deletion of Atg7 slows down melanoma cell growth in vivo , but not in vitro . Atg7 deletion also results in increased CD8+ T cells and reduced myelosuppressive cell infiltration in the tumor microenvironment, suggesting a strong immune system contribution in the role of Atg7 in melanoma progression. These findings highlight the complex interplay between genetic mutations, epigenetic regulators, and autophagy in shaping tumor immunity in melanoma. INTRODUCTION Epigenetic alterations contribute to oncogenesis through multiple mechanisms, from repression of tumor suppressor genes or activation of oncogenes to tumor cell extrinsic mechanisms such as angiogenesis, invasion and anti-tumor immunity 1 – 4 . Epigenetic regulators have thus become effective therapeutic targets in multiple solid tumors. One epigenetic complex that is frequently mutated in many solid tumors and directly implicated in antitumor immunity is the Polycomb Repressive Complex 2 and particularly its enzymatic domain, EZH2 5 , 6 . EZH2 possesses histone methyltransferase activity and mediates methylation of histone 3 on lysine 27 (H3K27me). Genetic alterations in EZH2 include both loss- and gain-of-function events, and it can function both as a tumor suppressor 7 – 11 and as an oncogene 12 – 16 . A unique point mutation in the methyltransferase domain of EZH2 (SET domain) at tyrosine 641 (Y641), alters its methyltransferase activity and may confer neomorphic functions by promoting unconventional changes to the distribution of H3K27me3 across the genome 12 , 17 , with complicated effects on gene expression. In previous studies, using a genetically engineered mouse model, we found that expression of mutant Ezh2 Y641F is oncogenic and cooperates with Braf V600E mutations and Pten loss to accelerate melanoma formation 12 . Furthermore, we found that mutant Ezh2 Y641F co-immunoprecipitates with Stat3, and together they activate expression of several common target genes. One class of genes co-regulated by Ezh2 and Stat3 in Ezh2 Y641F mutant melanomas were MHC class I antigen processing genes in the H2-Q cluster, which are directly implicated in anti-tumor immunity 18 . In addition to these MHC class I genes, chromatin immunoprecipitation followed by sequencing (ChIP-seq), suggests that Ezh2 and Stat3 are also found at the same promoter regions of the autophagy regulator, Atg7. Atg7 is a critical protein for autophagy initiation, as it facilitates an intermediate step in LC3 lipidation through its E1-like enzymatic activity 19 . Atg7 conjugates with and adenylates LC3 (a ubiquitin-like protein also known as Atg8) and then transfers LC3 to the E2-like enzyme Atg3, which catalyzes the conjugation of LC3 to phosphatidylethanolamine (PE) on the autophagosome membrane 20 , 21 . LC3 lipidation and, therefore, Atg7 are necessary for normal autophagosome formation, and Atg7 deficient cells are also autophagy deficient 19 , 22 . Autophagy plays a significant role in many different cellular functions, both cell-intrinsically and extrinsically. In cancer, numerous autophagy regulators are mutated or deregulated 23 – 25 , but given its role in many cellular mechanisms, its contribution during different phases of carcinogenesis is not entirely understood. In melanoma, previous studies have shown that deletion of Atg7 in a mouse model driven by the oncogenic Braf V600E and deletion of the tumor suppressor Pten significantly slowed down melanoma growth, suggesting that Atg7 functions as an oncogene 26 . Mechanistically, the study showed that deletion of Atg7 resulted in increased oxidative stress and cellular senescence, which served as a barrier to melanomagenesis 26 . Carcinogenesis, however, involves many different steps, from initial melanocyte transformation and immortalization to angiogenesis and immune evasion. The latter is particularly important in melanoma since checkpoint inhibitors have dramatically increased melanoma survival in the last ten years 27 – 30 . Despite this improvement, many patients do not respond to treatment or experience severe toxicity, necessitating better understanding of anti-tumor immune mechanisms. Many autophagy components have been implicated in tumor immunity in multiple solid tumors 31 – 35 , partially driven by their role in recycling unwanted cellular components and processing peptides, and may therefore play an important role in immunotherapy approaches. Given our prior findings that Ezh2 Y641F mutant melanomas have a significantly altered tumor immunity, and the fact that Ezh2 and Stat3 can both be found at the Atg7 locus, we hypothesized that Atg7 may contribute to the altered tumor immune response in Ezh2 Y641F melanomas. In this study we investigated the role of Atg7 in both Ezh2 WT and Ezh2 Y641F melanoma tumor growth and its effect on anti-tumor immunity. RESULTS Ezh2 and Stat3 regulate Atg7 expression in melanoma cells Previously, we investigated the role of Ezh2 Y641F mutations in melanoma and found a direct interaction of Ezh2 Y641F with Stat3, with direct effects on tumor immunity 18 . We also identified a number of loci directly bound by both Ezh2 and Stat3 in melanoma cells. Here, we expanded that study to additional cell lines to gain a more comprehensive understanding of genes regulated by both Ezh2 and Stat3 in melanoma in a Braf V600E /Pten F/F background, with or without the Ezh2 Y641F mutation. First, using Stat3 ChIP-seq, we confirmed enrichment of Stat3 binding motifs in Ezh2 Y641F melanoma cells compared to Ezh2 WT cells, and also identified enriched representation of motifs of other immune regulators, such as Stat1 and Irf1 ( Fig. 1a ). Gene Set Enrichment Analysis (GSEA) 36 of Stat3 peaks enriched in Ezh2 Y641F mutant melanoma cells identified several oncogenic signatures. Interestingly, we also identified several gene expression signatures that implicate autophagy or related cellular processes ( Fig. 1b ). We next assessed whether autophagy regulators were differentially expressed in Ezh2 WT vs Ezh2 Y641F melanoma 12 . We found that Atg7 , an important autophagy regulator, was upregulated in Ezh2 Y641F melanomas compared to Ezh2 WT , and its expression was downregulated upon treatment with a pharmacological Ezh2 inhibitor ( Fig. 1c ). We also found increased expression of Atg7 in Ezh2 Y641F melanoma cells at the protein level ( Fig. 1d ). Chromatin immunoprecipitation followed by sequencing (ChIP-seq) analysis identified several Stat3 and Ezh2 peaks at the Atg7 gene promoter and first intron ( Fig. 1f ). To confirm the relevance of these data in human patients, we analyzed data from the ReMap Atlas of regulatory regions (a collection of all public ChIP-seq data for transcriptional regulators from GEO, ArrayExpress, and ENCODE databases) 37 for EZH2 and STAT3 in various cell types and the ENCODE registry of candidate cis-regulatory elements 38 . We identified several cis-regulatory elements that coincide with mouse experimental Ezh2 and Stat3 binding sites ( Fig. 1e ), suggesting that our findings in mouse models are conserved and potentially relevant to human disease. Download figure Open in new tab Figure 1. Regulation of Atg7 expression by Ezh2 and Stat3 (a) Enriched motifs in Ezh2 WT and Ezh2 Y641F melanoma cells. (b) Gene Set Enrichment Analysis (GSEA) of Stat3 ChIP-seq peaks identifies several signatures associated with autophagy mechanisms (FDR<0.05). (c) Transcript expression of Atg7 in Ezh2 Y641F vs Ezh2 WT melanoma cells, in the absence or presence of the Ezh2 inhibitor JQEZ5. (d) Protein expression of Atg7 in Ezh2 WT vs Ezh2 Y641F melanoma cells by Western blot. (e) Human ChIP-seq data in various cell lines showing direct binding of both STAT3 (green) and EZH2 (blue) at the ATG7 promoter and intronic regions that correspond to cis-regulatory elements. Image modified from UCSC Genome Browser. (f) ChIP-seq tracks for Ezh2 and Stat3 in Ezh2 WT and Ezh2 Y641F melanoma cells at the mouse Atg7 locus indicating binding at the Atg7 promoter and first intron. Loss of Atg7 inhibits in vitro and in vivo cell growth To determine whether Stat3 controls expression of Atg7, we generated stable Stat3 knockdown melanoma cells lines using shRNA. We found that Stat3 knockdown in at least two independent mouse melanoma cell lines resulted in lower Atg7 protein levels, consistent with the hypothesis that Stat3 positively regulates Atg7 expression ( Fig. 2a-c ). Since Atg7 is an important regulator of autophagy initiation, we assessed the ratio of type I cytosolic LC3 (LC3-I) and the type II lipid-conjugated form that is present on autophagosome membranes (LC3-II), a standard assay for assessing autophagy 39 , 40 . We found that after Stat3 knockdown, cells exhibited a lower LC3-II/I ratio, indicating reduced levels of autophagy ( Fig. 2c ), consistent with depletion of Atg7 protein levels. We next investigated whether Atg7 is required for in vitro melanoma growth. We used a lentiviral CRISPR/Cas9 system to inactivate Atg7 expression in two Ezh2 WT and two Ezh2 Y641F melanoma cell lines. The lentiviral system is a single vector delivery of the single guide RNA (sgRNA) targeting Atg7, Cas9, puromycin for selection and GFP for cell sorting 41 . For controls we generated stable cell lines using two non-specific sgRNAs. After puromycin selection, GFP+ transfected cells were sorted by FACS and tested for knockout efficiency by Western blot. We identified multiple clones that exhibited small genomic deletions within the targeted exon and which resulted in complete loss of Atg7 protein expression ( Fig. 2d-e ). We further tested these clones for autophagy activity, and they exhibited a decreased LC3-II/I ratio, verifying disruption of Atg7 function and lower autophagic activity (n=4, p<0.05) ( Fig. 2d-e ). To determine whether absence of Atg7 affects cell intrinsic melanoma growth in vitro , we monitored cell growth using Alamar Blue staining, a cell-permeable dye, (resazurin), which serves as a redox indicator in response to cellular metabolic activity 42 . We found that deletion of Atg7 only transiently slowed the growth of Ezh2 WT cells, but did not have a significant overall effect during the duration of the in vitro assay ( Fig. 2f ), or an effect on the growth rate of Ezh2 Y641F melanoma cells. These results suggest that the effect of Atg7 deletion on melanoma cell growth may depend not only on increased cellular stress and senescence, as previously suggested 26 , but also on specific in vivo variables and cell extrinsic factors such as the tumor microenvironment and anti-tumor immunity. Download figure Open in new tab Figure 2. Deletion of Atg7 in melanoma cells has no significant effect on cell intrinsic cell growth in vitro (a) Protein expression of Stat3 after shRNA-mediated stable gene knockdown in melanoma cell line 234Δ. (b) Expression of Atg7 and LC3 after Stat3 knockdown in Ezh2 WT and Ezh2 Y641F melanoma cell lines 234 and 234Δ. (c) Quantification of western blot in b. Atg7/Actin N = 2, LC3-II/I N = 1. (d) (Top) Immunoblotting for Atg7 and LC3-I/II in control and Atg7 knockout clones in the 234 and 234Δ cell lines. NT, non-targeted sgRNA. (Bottom) Quantification of the plots above, Atg7/Gapdh and LC3-II/I N = 1. (e) As in (d), with a second set of Ezh2 WT (27.6-M2) and Ezh2 Y641F (28.2-M4) melanoma cell lines. Atg7/Gapdh N = 3, LC3-II/I N = 4. (f) In vitro growth curve of Ezh2 WT and Ezh2 Y641F melanoma cell lines 27.6-M2 and 28.2-M4 with and without Atg7 deletion. N.S. = not statistically significant. For all graphs error bars are standard deviation, *** p-value <0.001, * p-value <0.05. Atg7 deletion suppresses in vivo tumor growth and results in increased CD8+ T cells in the tumor microenvironment To test whether Atg7 deletion differentially affects in vivo growth of Ezh2 WT or Ezh2 Y641F mutant melanomas, we adaptively transferred five hundred thousand Atg7 knockout Ezh2 WT and Ezh2 Y641F melanoma cells into the left and right flank of wildtype recipient mice. These cells formed tumors, which we monitored for growth over time. Consistent with our prior finding, tumors expressing Ezh2 Y641F grew more slowly than Ezh2 WT 18 , and deletion of Atg7 resulted in slower tumor growth regardless of Ezh2 status (n=8, p<0.001 for WT Control vs all other groups at every time point) ( Fig. 3a ). These results are consistent with a prior study that demonstrated the oncogenic activity of Atg7 in a Braf V600E / Pten F/F background 26 , which was attributed to a cell intrinsic increase of oxidative stress and senescence of the tumor cells, without consideration of cell extrinsic variables. Since we previously showed that tumor immunity is an important factor in the progression of Ezh2 Y641F melanomas in vivo , we investigated how deletion of Atg7 affected infiltration of immune cells in Ezh2 WT and Ezh2 Y641F melanomas. We harvested tumors seven days after injection and analyzed tumor immune cell infiltration by flow cytometry. We found that the overall amount of CD45+ tumor infiltrating cells, while somewhat variable, tended to be higher after Atg7 deletion, particularly in Ezh2 WT melanoma tumors (n=8, p=0.024) ( Fig. 3b ). Nevertheless, we observed more significant differences in the type of immune cells that infiltrated these tumors. In the Ezh2 Y641F control group, we detected increased CD8+ T cell infiltration compared to Ezh2 WT (n=8, p<0.001), confirming our prior findings 18 . Deletion of Atg7 resulted in no change to CD8+ T cell infiltration in Ezh2 WT ; however, Atg7 deletion in Ezh2 Y641F tumors resulted in an approximately 2-fold increase in the CD8+ population (n=7-8, p<0.001) ( Fig. 3c-d ). Interestingly, we found that expression of Ezh2 Y641F , regardless of Atg7 expression, dramatically increased infiltration of natural killer (NK) cells, a population that we had not previously assessed in this model (n=7-8, p<0.001) ( Fig. 3c ). Other lymphoid populations such as CD4+ cells were elevated in Ezh2 Y641F compared to Ezh2 WT tumors, but deletion of Atg7 had no significant effect compared to the control group in either Ezh2 genotype ( Fig. 3c-d ). Download figure Open in new tab Figure 3. Deletion of Atg7 in melanoma cells results in slower in vivo tumor growth and increased presence of tumor infiltration of lymphocytes (a) (Left) In vivo tumor growth in Ezh2 WT (27.6M2) and Ezh2 Y641F (28.2M4) melanomas, with and without Atg7 deletion. The group average is displayed and error bars indicate the standard deviation. Control = non-targeted sgRNA, N = 8 per group, representative of two independent experiments. (Right) Tumor volume at day 5 post injection. The bars indicate the group mean, and the circles are individual tumors. (b) Flow cytometric analysis of tumor infiltrating CD45+ hematopoietic cells and CD45-cells. N = 6-8 tumors per group. (c) Flow cytometric analysis of tumor infiltrating CD8+, CD4+ and NK1.1+ cells. N = 7-8 tumors per group. (d) Representative flow cytometry plots of the CD4+ and CD8+ data shown in panel c. For the graphs in b and d, each dot on the graph represents an individual tumor, and the black bar marks the average for the group. *p<0.05, **p<0.01, ***p<0.001. While the number of cytotoxic CD8+ T cells significantly increased with Atg7 deletion in Ezh2 Y641F melanoma, it is possible that these T cells are not functionally competent killer cells. T cells have evolved mechanisms to prevent autoreactivity through receptor-ligand interactions, also known as immune checkpoints. These interactions are very important in cancer, as ligands expressed on tumors may interact with receptors on T cells to inhibit anti-tumor activity. One such immune checkpoint pair is PD-1 and PD-L1. We thus assessed the presence of the PD-1 on T cells in the tumor microenvironment, and PD-L1 on the melanoma cells. We found increased expression of PD-1 in CD8+ T cells after Atg7 knockout (n=7-8, p<0.001) and to a lesser degree in CD4+ cells ( Fig. 4a ). Ezh2 Y641F Atg7 knockout tumors also exhibited increased expression of PD-L1 compared to all other groups (p<0.05) ( Fig. 4b ). These data suggest that while loss of Atg7 results in slower tumor growth, likely partially mediated by increased presence of CD8+ T cells, it may also eventually lead to T cell exhaustion. Download figure Open in new tab Figure 4. Deletion of Atg7 in melanoma cells results in decreased infiltration of myelosuppressive cells. (a) Expression of PD1 on tumor infiltrating CD8+ and CD4+ T cells in Ezh2 WT and Ezh2 Y641F melanoma cells, with and without Atg7 deletion. N = 7-8 tumors per group. (b) Expression of the PD1 ligand (PD-L1) on the melanoma cells from panel a. N = 6-8 tumors per group. (c) Flow cytometric analysis of tumor infiltrated CD11c+, Mac1+ and double Mac1/Gr1+ cells in Ezh2 WT and Ezh2 Y641F melanoma tumors, with and without Atg7 deletion. N = 6-8 tumors per group. (d) Representative flow cytometry plots for the Mac1+ and double Mac1/Gr1+ data in panel c. For the graphs in a-c, each dot on the graph represents an individual tumor, and the black bar marks the average for the group. *p<0.05, **p<0.01, ***p<0.001. Deletion of Atg7 results in a decrease of myelosuppressive cells in the melanoma tumor microenvironment Another important immune population that plays a critical role in tumor immunity are myeloid-derived suppressor cells (MDSCs). To test whether Atg7 deletion affects infiltration of these cells in the melanoma tumor microenvironment, we measured expression of myeloid markers using flow cytometry. We found a significant decrease of Mac1+/Gr1+ double-positive cells after Atg7 deletion in both Ezh2 WT and Ezh2 Y641F cells (n=6-8, p<0.001 WT, p<0.05 Y641F), with a significantly lower frequency in the Ezh2 Y641F tumors (p=0.04), while Mac1+ cells decreased only in the Ezh2 Y641F Atg7 knockout tumors (n=6-8, p<0.01) ( Fig. 4c-d ). We did not find changes in the dendritic cell population as determined by CD11c expression in any of the groups, regardless of Ezh2 status or Atg7 expression ( Fig. 4c ). Overall, these results suggest that deletion of Atg7 affects the recruitment of both lymphoid and myeloid populations in the melanoma tumor microenvironment. Some of the observed phenotypes were stronger when Atg7 was deleted in the presence of Ezh2 Y641F , suggesting that some of the effects of Ezh2 Y641F on melanoma tumor immunity may be mediated by Atg7. It remains to be seen whether the effects of Atg7 on tumor immunity are mediated through its role in autophagy or whether they are mediated by autophagy-independent, cell intrinsic mechanisms. DISCUSSION In this study we investigated the role of downstream targets of Ezh2 in the melanoma tumor immune response. Ezh2 regulates many different hallmarks of cancer, from cell intrinsic cell cycle regulation to tumor immunity. Ezh2 has a complex role in cancer. It is often deleted in some cancers while amplified in others, consequently functioning both as a tumor suppressor and as an oncogene. While typically functioning within the PRC2 complex and mediating methylation of lysine 27 on histone 3, Ezh2 can also function independently of the PRC2 complex, sometimes as a transcriptional activator as we and others have previously shown 18 , 43 . Here we investigated the role of one of its non-canonical targets, Atg7, an autophagy regulator. Autophagy is a fundamental cellular mechanism required to maintain cellular health. When perturbed it can result in the onset of different diseases. In antigen-presenting cells, such as dendritic cells, autophagy generates peptides from endogenous antigens, which are presented by MHC class II proteins to CD4+ cells to prime the immune response. In cancer, the role of autophagy is context dependent. Autophagy in tumor cells can enhance processing of exogenous antigens and MHC-I antigen presentation, inducing CD8 T cell priming and cytotoxic activity 44 . Specifically, ATG genes, such as ATG7 , are involved in the internalization and recycling of the MHC-I molecules themselves 44 , and dendritic cells deficient in Atg7 have increased cell surface expression of MHC-I molecules 45 . Autophagy, therefore, can stimulate CD8+ T cells, thus functioning in a tumor suppressive manner 46 . In our melanoma models, it is possible that deletion of Atg7 similarly increases the amount of MHC-I at the cell surface, resulting in the increased CD8+ T cell infiltration that we observe in melanoma tumors. On the other hand, because cancer cells require autophagy for growth, autophagy-regulating genes can also function as oncogenes 26 . Consistent with an oncogenic function, in humans, melanoma patients with a high autophagic index benefit less from chemotherapy, exhibit increased tumor cell proliferation and metastasis, and have poor outcomes 47 , 48 . Overall, this dual role of autophagy in cancer is not well understood and may be context dependent. Within the context of Ezh2 Y641F -mutant melanomas, loss of Atg7 does not have a significant effect on cell intrinsic cell growth, but it appears to further enhance anti-tumor immunity with increased presence of cytotoxic CD8+ T cells and decreased MDSCs populations in the tumor microenvironment, a combination that is not conducive to tumor growth. Expression of Atg7 does not change dramatically with expression of Ezh2 Y641F , in vitro , but its expression is regulated by Stat3, as clearly demonstrated with Stat3 knock-down experiments. Ezh2 and Stat3 may, therefore, play a role in sustaining Atg7 expression within the context of a more complicated transcriptional network, and that Atg7 may be playing a secondary role in the many role of Ezh2 Y641F mutations in melanoma. Tumor immunobiology is very complex and is affected by a multitude of factors, including cell-intrinsic variables, the stroma, fibrosis, the tumor tissue location, the vasculature, tumor burden, signals or cytokines secreted by tumor cells, and others. It is possible that deletion of Atg7 affects any of these factors, whether via autophagy-dependent or -independent functions. Regardless of the mechanisms, our results indicate the relevance of tumor immunity in melanoma tumors lacking expression of Atg7 . Future studies are needed to further delineate mechanistically how Atg7 deletion results in such significant changes to the tumor immune response in melanoma and how it cooperates with mutations in Ezh2. With the availability of several pharmacological inhibitors of autophagy mechanisms, our study suggests that targeting autophagy-related pathways could be a viable strategy to modulate anti-tumor immunity, offering potential for therapeutic advancements in melanoma treatment. MATERIALS & METHODS Genomic analysis ChIP-seq and RNA-seq were performed on Ezh2 WT and Ezh2 Y641F mouse melanoma cells with or without treatment with the Ezh2 inhibitor JQEZ5 as described previously 18 . Analysis of transcription factor motif enrichment was carried out using HOMER 49 . Functional significance of Ezh2 and Stat3 binding sites/peaks was evaluated using the Genomic Regions Enrichment of Annotations Tool (GREAT) 50 and Gene Set Enrichment Analysis was performed as described here 36 . The UCSC Genome Browser was used to visualize EZH2 and STAT3 binding sites at the ATG7 locus (human GRCh38/hg38) using tracks for the ReMap Atlas of Regulatory Regions and the ENCODE Candidate Cis-Regulatory Elements (cCREs) 37 . Cell culture & CRISPR knockouts Eight mouse melanoma cell lines were used: 234, 480, and 855 ( Ezh2 WT Tyr-CRE ERT 2 Braf V600E/+ Pten flox/flox ); 234Δ, 480Δ, and 855Δ ( Ezh2 Y641F Tyr-CRE ERT 2 Braf V600E/+ Pten flox/flox ); 27.6-M2 ( Ezh2 WT Tyr-CRE ERT 2 Braf V600E/+ Pten flox/+ ); and 28.2-M4 ( Ezh2 Y641F Tyr-CRE ERT 2 Braf V600E/+ Pten flox/+ ). Cells were cultured in DMEM (Sigma D6429) with 10% FBS (Corning Cat# MT35010CV) and 1% penicillin-streptomycin (Genesee Scientific Cat# 25-512). Atg7 knockout cell lines were generated by transducing cells with lentiviral CRISPR/Cas9 (TLCV2 Addgene plasmid #87360). Lentiviruses were generated using 293T cells via transfection with PEI. Stable cell lines were selected by treating with puromycin for 7 days (3 µg/ml, refreshed every other day), and Cas9 expression was induced with 3-5 doses of doxycycline at 1 µg/ml. To generate single clones, GFP+ and PI negative cells were single cell sorted into 96 well plates on the MoFlo sorter (Beckman Coulter) at the Siteman Flow Cytometry Core Facility. The clones were tested for Atg7 knockout by immunoblotting. For the in vitro cell growth assay, cells were plated at 1000 cells/well in a 24-well plate in triplicate, one set of triplicates for each time point. For each measurement, the growth media was aspirated and replaced with media containing Alamar Blue (Invitrogen #A50100) cell viability reagent at 1:10 dilution 42 . The cells were returned to the incubator for 1 hour, after which 100 µl of supernatant was transferred from the 24-well plate to a clean 96-well plate. The samples were scanned on a BioTek Synergy HT plate reader using fluorescent excitation at 485/20 nm and detection at 590/35 nm. Data analysis was performed in Excel and statistically significant differences were determined by one-way ANOVA. Immunoblotting Samples were prepared in Laemmli buffer with beta-mercaptoethanol, run on 4-20% pre-cast gels (Bio-Rad Mini-PROTEAN TGX Gels Cat# 4561095) using the BioRad Mini-PROTEAN system, and then transferred onto nitrocellulose membranes. The membranes were blocked for 1 hour in 5% milk in TBS-T, and then incubated with primary antibodies overnight at 4°C. Primary antibodies: anti-ATG7 (Cell Signaling #8558 at 1:500), anti-ACTIN (Abcam ab213262 at 1:1000), anti-GAPDH (Cell Signaling #5174 at 1:1000), and anti-LC3A/B (Cell Signaling #12741 at 1:1000). Membranes were washed with TBS-T before staining with secondary anti-rabbit IgG (H+L) DyLight 800 4X PEG Conjugate (Cell Signaling #5151) at 1:20,000 at room temperature for 1 hour. Membranes were imaged using a Licor Odyssey Infrared Imager, and Image Studio software was used for densitometry analysis. Statistically significant differences were detected using one-way ANOVA. Animals Animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited facility and treated in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) for animal research at Washington University in St. Louis. In vivo tumor models Wildtype C57Bl/6 mice were generated in house. Tumor cells in Matrigel (Corning 354234) were injected subcutaneously in the flank at 0.5 × 10^6 cells per injection, two injections per mouse. Tumor growth was measured using digital calipers on day 5 post-injection and then every other day. For the flow cytometry analysis of tumor-infiltrating lymphocytes, tumors were harvested at day 7. Tumors were chopped in HBSS, dispersed using a syringe with 18G needle, and passed through a 0.40 µm filter. Flow Cytometric analysis Single cell suspensions from tumors were washed with HBSS containing 2% FBS and 1 mM EDTA and stained with the following antibody cocktails for detecting lymphoid populations: anti-CD45-PerCP/Cy5.5 (BioLegend 103132), anti-NK1.1-FITC (BioLegend 108706), anti-CD3-PB (BioLegend 100214), anti-CD4-APC (BioLegend 100412), anti-CD8-AF700 (BioLegend 100730), and anti-PD-1(CD279)-PE/Cy7 (BioLegend 135216), and myeloid populations: anti-CD45-PerCP/Cy5.5 (BioLegend 103132), anti-CD19-FITC (BioLegend 115506), anti-B220-FITC (BioLegend 103206), anti-CD3-FITC (BioLegend 100204), anti-CD11b(Mac1)-PB (BioLegend 101224), anti-CD11c-PE/Cy7 (BioLegend 117318), and anti-Ly-6G(Gr1)-AF700 (BioLegend 127622). Propidium Iodide was used to exclude dead cells. Samples were run on an Attune Nxt Flow Cytometer (ThermoFisher Scientific) at the Siteman Flow Cytometry Core Facility, analysis was done in FlowJo V10, and statistically significant differences were identified using One-way ANOVA. AUTHOR CONTRIBUTIONS GPS and SMZ designed experiments and wrote the manuscript. GPS, SMZ, ES and SS performed experiments, analyzed, and interpreted the data. ES and SS performed experiments. GPS conceived of and supervised the study. CONFLIC OF INTEREST The authors declare no relevant competing financial interests. ACKNOWLEDGEMENTS We thank the Siteman Flow Cytometry facility and the Department of Comparative Medicine for animal expertise. We also thank all members of the Souroullas lab for critical input on the manuscript. This work was supported by the Alvin J. Siteman Cancer Center, The Harry J. Lloyd Charitable Trust (GPS) and T32 CA113275-10 (SZ), Footnotes Conflict of Interests: The authors declare no potential conflicts of interest. REFERENCES ↵ Villanueva L , Álvarez-Errico D , Esteller M . The Contribution of Epigenetics to Cancer Immunotherapy . Trends in Immunology 2020 ; 41 : 676 – 691 . OpenUrl ↵ Hogg SJ , Beavis PA , Dawson MA , Johnstone RW . Targeting the epigenetic regulation of antitumour immunity . Nature Reviews Drug Discovery 2020 ; 19 : 776 – 800 . OpenUrl CrossRef Feinberg AP , Koldobskiy MA , Göndör A . Epigenetic modulators, modifiers and mediators in cancer aetiology and progression . Nature Publishing Group 2016 ; 17 : 284 – 299 . OpenUrl ↵ Jones PA , Baylin SB . The fundamental role of epigenetic events in cancer . Nat Rev Genet 2002 ; 3 : 415 – 428 . OpenUrl CrossRef PubMed Web of Science ↵ Gao J , Aksoy BA , Dogrusoz U , Dresdner G , Gross B , Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal . Science Signaling 2013 ; 6 : pl1 – pl1 . OpenUrl Abstract / FREE Full Text ↵ Cerami E , Gao J , Dogrusoz U , Gross BE , Sumer SO , Aksoy BA et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1 . Cancer Discovery 2012 ; 2 : 401 – 404 . OpenUrl Abstract / FREE Full Text ↵ Ntziachristos P , Tsirigos A , Vlierberghe PV , Nedjic J , Trimarchi T , Flaherty MS et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia . Nature Medicine 2012 ; 18 : 298 – 302 . OpenUrl CrossRef PubMed Muto T , Sashida G , Oshima M , Wendt GR , Mochizuki-Kashio M , Nagata Y et al. Concurrent loss of Ezh2and Tet2cooperates in the pathogenesis of myelodysplastic disorders . J Exp Med 2013 ; 210 : 2627 – 2639 . OpenUrl Abstract / FREE Full Text Clair JM-S , Soydaner-Azeloglu R , Lee KE , Taylor L , Livanos A , Pylayeva-Gupta Y et al. EZH2 couples pancreatic regeneration to neoplastic progression . Genes & development 2012 ; 26 : 439 – 444 . OpenUrl Abstract / FREE Full Text Wang Y , Hou N , Cheng X , Zhang J , Tan X , Zhang C et al. Ezh2 acts as a tumor suppressor in kras-driven lung adenocarcinoma . International Journal of Biological Sciences 2017 ; 13 : 652 . OpenUrl ↵ Mochizuki-Kashio M , Aoyama K , Sashida G , Oshima M , Tomioka T , Muto T et al. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner . Blood 2015 ; 126 : 1172 – 1183 . OpenUrl Abstract / FREE Full Text ↵ Souroullas GP , Jeck WR , Parker JS , Simon JM , Liu J-Y , Paulk J et al. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation . Nature Medicine 2016 ; 22 : 632 – 640 . OpenUrl CrossRef PubMed Zingg D , Debbache J , Schaefer SM , Tuncer E , Frommel SC , Cheng P et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors . Nature Communications 2015 ; 6 : 6051 . OpenUrl Béguelin W , Popovic R , Teater M , Jiang Y , Bunting KL , Rosen M et al. EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation . Cancer Cell 2013 ; 23 : 677 – 692 . OpenUrl CrossRef PubMed Web of Science Varambally S , Dhanasekaran SM , Zhou M , Barrette TR , Kumar-Sinha C , Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer . Nature 2002 ; 419 : 624 – 629 . OpenUrl CrossRef PubMed Web of Science ↵ Zhang H , Qi J , Reyes JM , Li L , Rao PK , Li F et al. Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer . Cancer Discov 2016 ; 6 : 1006 – 1021 . OpenUrl Abstract / FREE Full Text ↵ Romero P , Richart L , Aflaki S , Petitalot A , Burton M , Michaud A et al. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition . Nat Commun 2024 ; 15 : 3452 . OpenUrl ↵ Zimmerman SM , Nixon SJ , Chen PY , Raj L , Smith SR , Paolini RL et al. Ezh2Y641F mutations co-operate with Stat3 to regulate MHC class I antigen processing and alter the tumor immune response in melanoma . Oncogene 2022 . doi: 10.1038/s41388-022-02492-7 . OpenUrl CrossRef ↵ Collier JJ , Suomi F , Oláhová M , McWilliams TG , Taylor RW . Emerging roles of ATG7 in human health and disease . EMBO Mol Med 2021 ; 13 . doi: 10.15252/emmm.202114824 . OpenUrl CrossRef ↵ Ichimura Y , Kirisako T , Takao T , Satomi Y , Shimonishi Y , Ishihara N et al. A ubiquitin-like system mediates protein lipidation . Nature 2000 ; 408 : 488 – 492 . OpenUrl CrossRef PubMed Web of Science ↵ Taherbhoy AM , Tait SW , Kaiser SE , Williams AH , Deng A , Nourse A et al. Atg8 transfer from Atg7 to Atg3: a distinctive E1-E2 architecture and mechanism in the autophagy pathway . Mol Cell 2011 ; 44 : 451 – 461 . OpenUrl CrossRef PubMed Web of Science ↵ Komatsu M , Waguri S , Ueno T , Iwata J , Murata S , Tanida I et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice . J Cell Biol 2005 ; 169 : 425 – 434 . OpenUrl Abstract / FREE Full Text ↵ Wen X , Klionsky DJ . At a glance: A history of autophagy and cancer . Semin Cancer Biol 2020 ; 66 : 3 – 11 . OpenUrl Li X , He S , Ma B . Autophagy and autophagy-related proteins in cancer . Mol Cancer 2020 ; 19 : 12 . ↵ Debnath J , Gammoh N , Ryan KM . Autophagy and autophagy-related pathways in cancer . Nat Rev Mol Cell Biol 2023 ; 24 : 560 – 575 . OpenUrl ↵ Xie X , Koh JY , Price S , White E , Mehnert JM . Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma . Cancer Discovery 2015 ; 5 : 410 – 423 . OpenUrl Abstract / FREE Full Text ↵ Js W , Kc K , A H . Management of immune-related adverse events and kinetics of response with ipilimumab . Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012 ; 30 . doi: 10.1200/JCO.2012.41.6750 . OpenUrl Abstract / FREE Full Text Robert C , Long GV , Brady B , Dutriaux C , Maio M , Mortier L et al. Nivolumab in previously untreated melanoma without BRAF mutation . N Engl J Med 2015 ; 372 : 320 – 330 . OpenUrl CrossRef PubMed Web of Science Linardou H , Gogas H . Toxicity management of immunotherapy for patients with metastatic melanoma . Annals of Translational Medicine 2016 ; 4 : 272 – 272 . OpenUrl ↵ Patel Sapna P. , Othus Megan , Chen Yuanbin , Wright G. Paul , Yost Kathleen J. , Hyngstrom John R. , et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma . New England Journal of Medicine 2023 ; 388 : 813 – 823 . OpenUrl CrossRef ↵ Xia H , Green DR , Zou W . Autophagy in tumour immunity and therapy . Nat Rev Cancer 2021 ; 21 : 281 – 297 . OpenUrl Van Kaer L , Parekh VV , Postoak JL , Wu L . Role of autophagy in MHC class I-restricted antigen presentation . Molecular Immunology 2019 ; 113 : 2 – 5 . OpenUrl Chemali M , Radtke K , Desjardins M , English L . Alternative pathways for MHC class I presentation: a new function for autophagy . Cell Mol Life Sci 2011 ; 68 : 1533 – 1541 . OpenUrl CrossRef PubMed Yamamoto K , Venida A , Yano J , Biancur DE , Kakiuchi M , Gupta S et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I . Nature 2020 ; 581 : 100 – 105 . OpenUrl CrossRef PubMed ↵ Valečka J , Almeida CR , Su B , Pierre P , Gatti E . Autophagy and MHC-restricted antigen presentation . Mol Immunol 2018 ; 99 : 163 – 170 . OpenUrl CrossRef ↵ Subramanian A , Tamayo P , Mootha VK , Mukherjee S , Ebert BL , Gillette MA et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles . Proceedings of the National Academy of Sciences 2005 ; 102 : 15545 – 15550 . OpenUrl Abstract / FREE Full Text ↵ Hammal F , de Langen P , Bergon A , Lopez F , Ballester B. ReMap 2022: a database of Human, Mouse, Drosophila and Arabidopsis regulatory regions from an integrative analysis of DNA-binding sequencing experiments . Nucleic Acids Research 2022 ; 50 : D316 – D325 . OpenUrl CrossRef PubMed ↵ The ENCODE Project Consortium , Abascal F , Acosta R , Addleman NJ , Adrian J , Afzal V et al. Expanded encyclopaedias of DNA elements in the human and mouse genomes . Nature 2020 ; 583 : 699 – 710 . OpenUrl CrossRef PubMed ↵ Mizushima N , Yoshimori T , Levine B . Methods in mammalian autophagy research . Cell 2010 ; 140 : 313 – 326 . OpenUrl CrossRef PubMed Web of Science ↵ Singh B , Bhaskar S . Methods for Detection of Autophagy in Mammalian Cells . Methods Mol Biol 2019 ; 2045 : 245 – 258 . OpenUrl CrossRef ↵ Barger CJ , Branick C , Chee L , Karpf AR . Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer . Cancers (Basel) 2019 ; 11 : 251 . ↵ Kumar P , Nagarajan A , Uchil PD . Analysis of Cell Viability by the alamarBlue Assay . Cold Spring Harb Protoc 2018 ; 2018 . doi: 10.1101/pdb.prot095489 . OpenUrl Abstract / FREE Full Text ↵ Zimmerman SM , Lin PN , Souroullas GP . Non-canonical functions of EZH2 in cancer . Frontiers in Oncology 2023 ; 13 . https://www.frontiersin.org/articles/10.3389/fonc.2023.1233953 ( accessed 17 Jan2024 ). ↵ Fonderflick L , Adotévi O , Guittaut M , Adami P , Delage-Mourroux R. Role of autophagy in antigen presentation and its involvement on cancer immunotherapy . In: Autophagy in Immune Response: Impact on Cancer Immunotherapy . Elsevier , 2020 , pp 175 – 196 . ↵ Loi M , Müller A , Steinbach K , Niven J , Barreira da Silva R , Paul P et al. Macroautophagy Proteins Control MHC Class I Levels on Dendritic Cells and Shape Anti-viral CD8 + T Cell Responses . Cell Reports 2016 ; 15 : 1076 – 1087 . OpenUrl ↵ Liang C , Feng P , Ku B , Dotan I , Canaani D , Oh B-H et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG . Nat Cell Biol 2006 ; 8 : 688 – 698 . OpenUrl CrossRef PubMed Web of Science ↵ Ma X-H , Piao S , Wang D , Mcafee QW , Nathanson KL , Lum JJ et al. Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma . Clin Cancer Res 2011 ; 17 : 3478 – 3489 . OpenUrl Abstract / FREE Full Text ↵ Lazova R , Camp RL , Klump V , Siddiqui SF , Amaravadi RK , Pawelek JM . Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome . Clin Cancer Res 2012 ; 18 : 370 – 379 . OpenUrl Abstract / FREE Full Text ↵ Heinz S , Benner C , Spann N , Bertolino E , Lin YC , Laslo P et al. Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities . Molecular Cell 2010 ; 38 : 576 – 589 . OpenUrl CrossRef PubMed Web of Science ↵ McLean CY , Bristor D , Hiller M , Clarke SL , Schaar BT , Lowe CB et al. GREAT improves functional interpretation of cis -regulatory regions . Nature Biotechnology 2010 ; 28 : 495 – 501 . OpenUrl CrossRef PubMed Web of Science View the discussion thread. Back to top Previous Next Posted June 12, 2024. Download PDF Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Stat3-mediated Atg7 expression enhances anti-tumor immunity in melanoma Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Stat3-mediated Atg7 expression enhances anti-tumor immunity in melanoma Sarah M. Zimmerman , Erin Suh , Sofia R. Smith , George P. Souroullas bioRxiv 2024.06.10.598284; doi: https://doi.org/10.1101/2024.06.10.598284 Share This Article: Copy Citation Tools Stat3-mediated Atg7 expression enhances anti-tumor immunity in melanoma Sarah M. Zimmerman , Erin Suh , Sofia R. Smith , George P. Souroullas bioRxiv 2024.06.10.598284; doi: https://doi.org/10.1101/2024.06.10.598284 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Cancer Biology Subject Areas All Articles Animal Behavior and Cognition (7643) Biochemistry (17717) Bioengineering (13910) Bioinformatics (42018) Biophysics (21480) Cancer Biology (18629) Cell Biology (25537) Clinical Trials (138) Developmental Biology (13392) Ecology (19935) Epidemiology (2067) Evolutionary Biology (24356) Genetics (15617) Genomics (22531) Immunology (17755) Microbiology (40438) Molecular Biology (17200) Neuroscience (88706) Paleontology (667) Pathology (2840) Pharmacology and Toxicology (4832) Physiology (7657) Plant Biology (15171) Scientific Communication and Education (2046) Synthetic Biology (4304) Systems Biology (9828) Zoology (2272)